Bioxytran (BIXT) Net Margin (2010 - 2018)

Bioxytran (BIXT) posted Net Margin of 1.35% for Q2 2018, up 99.39% sequentially from 222.39% in Q1 2018, and up 65840.0% YoY from N/an in Q2 2017.

Bioxytran (BIXT) Net Margin (2010 - 2018) Analysis & Trends

Bioxytran has reported Net Margin for 9 years, with the latest figure at 1.35% in Q2 2018.

Quarterly Net Margin rose 65840.0% year-over-year to 1.35% in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 36.82% (up 15853.0% YoY) and the FY2017 annual result came in at 166.63%, up 11604.0% from the prior year.
Net Margin improved to 1.35% in Q2 2018 per BIXT's latest filing, from 222.39% in the prior quarter.
Over five years, Net Margin peaked at 1947.24% in Q4 2014 and troughed at 3225.6% in Q2 2015.
A 5-year average of 422.71% and a median of 182.62% in 2016 frame the typical range for Net Margin.
The sharpest annual moves came in 2015 and 2016: Net Margin tumbled 307193 bps in 2015, then soared 296436 bps in 2016.
Over 5 years, Net Margin stood at 1947.24% in 2014, then plunged by 99 bps to 16.96% in 2015, then jumped by 1278 bps to 233.81% in 2016, then sank by 215 bps to 268.45% in 2017, then soared by 99 bps to 1.35% in 2018.
According to Business Quant data, Net Margin over the past three periods registered 1.35%, 222.39%, and 268.45% for Q2 2018, Q1 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.23%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	31.16%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	12.74%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-16.51%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	12.09%
10	Bioxytran	2.52 Mn	2.27 Mn	-	-

Download Data